Search Result

Results for "

motor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (6) Adenosine Receptor (2) Adrenergic Receptor (1) Akt (2) Apoptosis (1) ATF6 (1) Calcium Channel (3) Cathepsin (1) CDK (1) Cholinesterase (ChE) (3) COMT (1) CRFR (2) CXCR (2) DNA/RNA Synthesis (8) Dopamine Receptor (7) Dopamine Transporter (1) Drug Metabolite (2) Endogenous Metabolite (1) Eukaryotic Initiation Factor (eIF) (1) GCGR (1) GPR55 (1) Hedgehog (1) Histamine Receptor (2) Histone Acetyltransferase (1) HSP (4) iGluR (2) Imidazoline Receptor (1) Isotope-Labeled Compounds (4) Kinesin (6) mGluR (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Myosin (1) Neurokinin Receptor (1) Neurotensin Receptor (1) NO Synthase (2) Nuclear Hormone Receptor 4A/NR4A (1) Opioid Receptor (1) Parasite (1) Phosphodiesterase (PDE) (4) Potassium Channel (6) PPAR (1) Proteasome (1) Reactive Oxygen Species (1) Serotonin Transporter (1) Sigma Receptor (3) Sodium Channel (2) α-synuclein (1)
By Research Areas:	Cancer (12) Cardiovascular Disease (3) Endocrinology (1) Infection (2) Inflammation/Immunology (4) Metabolic Disease (7) Neurological Disease (66)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-135869

Mito-apocynin (C11) 2 Publications Verification	Mitochondrial Metabolism	Neurological Disease
Mito-apocynin (C11), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP ⁺ cation. Mito-apocynin (C11) selectively targets mitochondria, and shows neuroprotective effect. Mito-apocynin (C11) prevents hyposmia and corrects deficits in motor function .

HY-110125

ML-193 CID 1261822	GPR55	Neurological Disease
ML-193 (CID 1261822) is a potent and selective antagonist of GPR55, with an IC₅₀ of 221 nM. ML-193 shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2. ML-193 can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats .

HY-12501A

ITI-214 3 Publications Verification	Phosphodiesterase (PDE)	Neurological Disease
ITI-214 is a potent, CNS-active, orally bioavailable PDE1 inhibitor (K_i of 58 pM) with excellent selectivity against other PDE family members and against a panel of enzymes, receptors, transporters and ion channels. ITI-214 inhibits recombinant full-length human PDE1A, PDE1B and PDE1C with K_is of 33 pM, 380 pM and 35 pM, respectively. ITI-214 shows efficacy in various animal models of motor and cognitive functions .

HY-B1808A

Triprolidine hydrochloride	Histamine Receptor	Neurological Disease Inflammation/Immunology
Triprolidine hydrochloride is an orally active histamine H1 antagonist. Triprolidine hydrochloride has the function of spinal cord motor and sensory block. Triprolidine hydrochloride can be used for the research of allergic rhinitis .

HY-B1808

Triprolidine	Histamine Receptor	Infection
Triprolidine is an orally active H1R Antagonist antagonist. Triprolidine has the function of spinal cord motor and sensory block. Triprolidine can be used for the research of allergic rhinitis .

HY-106443A

Arimoclomol maleate 2 Publications Verification BRX-220	HSP	Neurological Disease Metabolic Disease Inflammation/Immunology
Arimoclomol maleate (BRX-220) is a co-inducer of heat shock proteins (HSP) . Arimoclomol protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system .

HY-12501

ITI-214 free base	Phosphodiesterase (PDE)	Neurological Disease
ITI-214 free base is a potent, CNS-active, orally bioavailable PDE1 inhibitor (K_i of 58 pM) with excellent selectivity against other PDE family members and against a panel of enzymes, receptors, transporters and ion channels. ITI-214 free base inhibits recombinant full-length human PDE1A, PDE1B and PDE1C with K_is of 33 pM, 380 pM and 35 pM, respectively. ITI-214 free base shows efficacy in various animal models of motor and cognitive functions .

HY-148867

UCM-1306 2-(Fluoromethoxy)-4'-(S-methylsulfonimidoyl)-1,1'-biphenyl	Dopamine Receptor	Neurological Disease
UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD) .

HY-16062

ARQ 621	Kinesin	Cancer
ARQ 621 is an allosteric, potent and selective inhibitor of Eg5, a microtubule-based ATPase motor protein involved in cell division. Anti-tumor activity . ARQ 621 is a kinesin inhibitor . ARQ 621 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-106443

Arimoclomol BRX-220 free base	HSP	Neurological Disease Metabolic Disease Inflammation/Immunology
Arimoclomol (BRX-220 free base) is a co-inducer of heat shock proteins (HSP) . Arimoclomol protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system .

HY-149941

hNTS1R agonist-1	Neurotensin Receptor	Neurological Disease
hNTS1R agonist-1 (Compound 10) is a BBB permeable hNTS1R full agonist (K_i: 6.9 nM) . hNTS1R agonist-1 increases motor function and memory in a mouse model of Parkinson's disease (PD). hNTS1R agonist-1 is a Neurotensin(8-13) analog and is a neuroprotective agent .

HY-106443B

Arimoclomol citrate BRX-220 citrate	HSP	Neurological Disease Metabolic Disease Inflammation/Immunology
Arimoclomol citrate (BRX-220 citrate) is a co-inducer of heat shock proteins (HSP) . Arimoclomol citrate protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system .

HY-N11128

Solidagonic acid	Kinesin	Cancer
Solidagonic acid inhibits HSET motor activity by promoting the conversion from abnormal monopolar to bipolar spindles. Solidagonic acid suppresses fission yeast cell death and enables reversion of the mitotic spindles from a monopolar to bipolar morphology. Solidagonic acid showed the growth inhibitory activity on the seedlings of Lactuca sativa L. and Lolium multiflorum Lam .

HY-124713

ML372	DNA/RNA Synthesis	Neurological Disease
ML372 inhibits survival motor neuron (SMN) protein ubiquitination, increases SMN protein stability without affecting mRNA expression. ML372 improves spinal muscular atrophy (SMA) in mice. ML372 is brain penetrant and has a reasonable exposure and half-life in vivo .

HY-111520

NVS-SM2	DNA/RNA Synthesis	Neurological Disease
NVS-SM2 is a potent, orally active and brain-penetrant SMN2 splicing enhancer with an EC₅₀ of 2 nM for SMN. NVS-SM2 enhances U1-pre-mRNA association. NVS-SM2 promotes exon 7 inclusion and restores normal survival motor neuron (SMN) protein expression. NVS-SM2 can be used for spinal muscular atrophy (SMA) research .

HY-18596

SB-215505	5-HT Receptor	Neurological Disease
SB-215505 is a potent and subtype-selective 5-HT_2B receptor antagonist with pK_i values of 8.3, 6.77, 7.66 for 5-HT_2B, 5-HT_2A, 5-HT_2C, respectively . SB-215505 increases wakefulness and motor activity in rats .

HY-103112

SB 243213 hydrochloride	5-HT Receptor	Neurological Disease
SB 243213 hydrochloride is an orally active, selective and high-affinity 5-HT_2C receptor antagonist with a pK_i of 9.37 and a pK_b of 9.8 for human 5-HT_2C receptor. SB 243213 hydrochloride shows greater than a 100-fold selectivity over a wide range of neurotransmitter receptors, enzymes and ion channels. SB 243213 hydrochloride has improved anxiolytic profile and has the potential for schizophrenia and motor disorders .

HY-103112A

SB 243213 dihydrochloride	5-HT Receptor	Neurological Disease
SB 243213 dihydrochloride is an orally active, selective and high-affinity 5-HT_2C receptor antagonist with a pK_i of 9.37 and a pK_b of 9.8 for human 5-HT_2C receptor. SB 243213 dihydrochloride shows greater than a 100-fold selectivity over a wide range of neurotransmitter receptors, enzymes and ion channels. SB 243213 dihydrochloride has improved anxiolytic profile and has the potential for schizophrenia and motor disorders .

HY-103112B

SB 243213	5-HT Receptor	Neurological Disease
SB 243213 is an orally active, selective and high-affinity 5-HT_2C receptor antagonist with a pK_i of 9.37 and a pK_b of 9.8 for human 5-HT_2C receptor. SB 243213 shows greater than a 100-fold selectivity over a wide range of neurotransmitter receptors, enzymes and ion channels. SB 243213 has improved anxiolytic profile and has the potential for schizophrenia and motor disorders .

HY-19620

Branaplam 5+ Cited Publications LMI070; NVS-SM1	DNA/RNA Synthesis Potassium Channel	Cancer
Branaplam (LMI070; NVS-SM1) is a highly potent, selective and orally active *survival motor* neuron-2 (SMN2) splicing modulator with an EC₅₀ of 20 nM for SMN. Branaplam inhibits human-ether-a-go-go-related gene (hERG) with an IC₅₀** of 6.3 μM. Branaplam elevates full-length SMN protein and extends survival in a severe spinal muscular atrophy (SMA) mouse model .

HY-19620A

Branaplam hydrochloride 5+ Cited Publications LMI070 hydrochloride; NVS-SM1 hydrochloride	DNA/RNA Synthesis Potassium Channel	Cancer
Branaplam (LMI070; NVS-SM1) hydrochloride is a highly potent, selective and orally active *survival motor* neuron-2 (SMN2) splicing modulator with an EC₅₀ of 20 nM for SMN. Branaplam hydrochloride inhibits human-ether-a-go-go-related gene (hERG) with an IC₅₀** of 6.3 μM. Branaplam hydrochloride elevates full-length SMN protein and extends survival in a severe spinal muscular atrophy (SMA) mouse model .

HY-15857

CW-069

1 Publications Verification

Kinesin Cancer

CW-069 is an allosteric inhibitor of microtubule motor protein HSET with an IC₅₀ of 75 μM.
HY-B1376

Methsuximide

Mesuximide; Celontin

Methsuximide is an anticonvulsant agent. Methsuximide is effective in petit mal, psychomotor and focal motor attacks .
HY-101770

BTB-1

Microtubule/Tubulin Cancer

BTB-1 is a potent, selective and reversible mitotic motor protein Kif18A inhibitor with an IC₅₀ of 1.69 μM.

CW-069 1 Publications Verification	Kinesin	Cancer
CW-069 is an allosteric inhibitor of *microtubule motor* protein HSET with an IC₅₀** of 75 μM.

Methsuximide Mesuximide; Celontin
Methsuximide is an anticonvulsant agent. Methsuximide is effective in petit mal, psychomotor and focal motor attacks .

BTB-1	Microtubule/Tubulin	Cancer
BTB-1 is a potent, selective and reversible mitotic motor protein Kif18A inhibitor with an IC₅₀ of 1.69 μM.

HY-18100A

PRE-084 hydrochloride 5+ Cited Publications	Sigma Receptor Akt NO Synthase	Cardiovascular Disease Neurological Disease
PRE-084 hydrochloride is a highly selective σ1 receptor (S1R) agonist, with an IC₅₀ of 44 nM. PRE-084 hydrochloride exhibits good neuroprotective effects, can improve motor function and motor neuron survival in mice. PRE-084 hydrochloride also can ameliorate myocardial ischemia-reperfusion injury in rats by activating the Akt-eNOS pathway .

HY-18100

PRE-084	Sigma Receptor Akt NO Synthase	Cardiovascular Disease Neurological Disease
PRE-084 is a highly selective σ1 receptor (S1R) agonist, with an IC₅₀ of 44 nM. PRE-084 exhibits good neuroprotective effects, can improve motor function and motor neuron survival in mice. PRE-084 also can ameliorate myocardial ischemia-reperfusion injury in rats by activating the Akt-eNOS pathway .

HY-B1007

Butacaine 2 Publications Verification	Others	Neurological Disease
Butacaine is a reversible nerve conduction blocker. Butacaine acts on the nervous system and nerve fibers, can cause both sensory and motor paralysis .

HY-B1430

Butamben Butyl 4-aminobenzoate	Calcium Channel Sodium Channel Potassium Channel	Neurological Disease
Butamben (Butyl 4-aminobenzoate) results in long-lasting relief from pain, without impairing motor function or other sensory functions .

HY-109101

Risdiplam 5+ Cited Publications RG7916; RO7034067	DNA/RNA Synthesis	Neurological Disease
Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed *SMN2* pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels .

HY-P1297

CRF(6-33)(human)	CRFR	Neurological Disease
CRF(6-33)(human) is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) has anti-obesity effect .

HY-P1297A

CRF(6-33)(human) TFA	CRFR	Neurological Disease
CRF(6-33)(human) TFA is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) TFA competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) TFA has anti-obesity effect .

HY-12788

PF-04449613	Phosphodiesterase (PDE)	Neurological Disease
PF-04449613 is a selective PDE9A inhibitor with an IC50 of 22 nM[1]. PF-04449613 improved motor learning ability in a mouse model[2].

HY-19530

PF-2771	Kinesin	Cancer
PF-2771 is a potent and selective centromere protein E (CENP-E) inhibitor, inhibiting CENP-E motor activity with an IC₅₀ of 16.1 nM; PF-2771 is used as an anticancer agent.

HY-14896

Opicapone 3 Publications Verification BIA 9-1067	COMT	Neurological Disease
Opicapone (BIA 9-1067) is a potent third-generation catechol-O-methyltransferase (COMT) inhibitor for the research of Parkinson's disease and motor fluctuations. Opicapone decreases the ATP content of the cells with an IC₅₀ of 98 μM .

HY-B1971S

Deltamethrin-d5 Decamethrin-d₅	Isotope-Labeled Compounds Endogenous Metabolite	Cancer
Deltamethrin-d₅ is the deuterium labeled Deltamethrin. Deltamethrin (Decamethrin), a neurotoxic pyrethroid insecticide, produces a reversible sequence of motor symptoms in rats involving hind limb rigidity and choreoathetosis[1][2].

HY-B1301

Triprolidine hydrochloride monohydrate
Triprolidine hydrochloride monohydrate, a first-generation antihistamine, is an oral active histamine H1 antagonist. Triprolidine hydrochloride monohydrate can be used for the research of allergic rhinitis. Triprolidine hydrochloride monohydrate exhibits spinal motor and sensory block in rats .

HY-W129456

Isaxonine	Others	Neurological Disease
Isaxonine acts as a modifier of the surface pH of the bilayer . Isaxonine accelerates the rate of peripheral nerve regeneration, stimulate axonal sprouting and promote motor and sensory function recovery . Isaxonine is a neurotrophic agent .

HY-10299

GSK-923295 Maximum Cited Publications 32 Publications Verification	Kinesin Apoptosis	Cancer
GSK-923295 is a special, allosteric inhibitor of centromere-associated protein-E (CENP-E) kinesin motor ATPase activity, with K_i of 3.2±0.2 nM and 1.6± 0.1 nM for human and canine, respectively.

HY-14408

Lu AA47070	Adenosine Receptor	Neurological Disease
Lu AA47070 is a phosphonooxymethylene prodrug of a potent and selective Adenosine A2A receptor antagonist. Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade .

HY-B0411

Domperidone 5 Publications Verification R33812	Dopamine Receptor	Neurological Disease
Domperidone (R33812) is an orally active and selective dopamine-2 receptor antagonist. Domperidone acts as an antiemetic and a prokinetic agent through its effects on the chemoreceptor trigger zone and motor function of the stomach and small intestine .

HY-B1430S

Butamben-d9 Butyl 4-aminobenzoate-d₉	Isotope-Labeled Compounds Calcium Channel Sodium Channel Potassium Channel	Neurological Disease
Butamben-d₉ is the deuterium labeled Butamben. Butamben (Butyl 4-aminobenzoate) results in long-lasting relief from pain, without impairing motor function or other sensory functions[1][2].

HY-109101S

Risdiplam-d4	DNA/RNA Synthesis	Neurological Disease
Risdiplam-d₄ is deuterium labeled Risdiplam. Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels[1].

HY-B0411A

Domperidone monomaleate 5 Publications Verification R33812 monomaleate
Domperidone (R33812) monomaleate is an orally active and selective dopamine-2 receptor antagonist. Domperidone monomaleate acts as an antiemetic and a prokinetic agent through its effects on the chemoreceptor trigger zone and motor function of the stomach and small intestine .

HY-41076

Ca2+ channel agonist 1	Calcium Channel CDK	Neurological Disease
Ca ²⁺ channel agonist 1 is an agonist of N-type Ca ²⁺ channel and an inhibitor of Cdk2, with EC₅₀s of 14.23 μM and 3.34 μM, respectively, and is used as a potential treatment for motor nerve terminal dysfunction.

HY-155134

Eg5-IN-1

Kinesin Cancer

Eg5-IN-1 (compound 6c) is a potent kinesin family motor protein (Eg5) inhibitor with an IC₅₀ value of 1.97 µM. Eg5-IN-1 can be used in research of cancer .

Eg5-IN-1	Kinesin	Cancer
Eg5-IN-1 (compound 6c) is a potent *kinesin family motor* protein (Eg5) inhibitor with an IC₅₀** value of 1.97 µM. Eg5-IN-1 can be used in research of cancer .

HY-109101AS1

Risdiplam-hydroxylate-d3	Isotope-Labeled Compounds DNA/RNA Synthesis	Neurological Disease
Risdiplam-hydroxylate-d₃ is a Risdiplam-hydroxylate tritium substitute. Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels .

HY-109101AS2

Risdiplam-hydroxylate-d6	Isotope-Labeled Compounds DNA/RNA Synthesis	Neurological Disease
Risdiplam-hydroxylate-d₆ is a Risdiplam-hydroxylate tritium substitute. Risdiplam (RG7916) is an orally administered, centrally and peripherally distributed SMN2 pre-mRNA splicing modifier that increases survival motor neuron (SMN) protein levels .

HY-14149

Cisapride 1 Publications Verification R 51619; (±)-Cisaprid	5-HT Receptor Potassium Channel	Neurological Disease
Cisapride (R 51619) is an orally active 5-HT₄ receptor agonist with an EC₅₀ value of 140 nM. Cisapride is a hERG blocker with an IC₅₀ value of 9.4 nM. Cisapride is a gastroprokinetic agent that stimulates gastrointestinal motor activity .

HY-122632

Ciliobrevin D 1 Publications Verification	Hedgehog	Cancer
Ciliobrevin D is a cell-permeable, reversible and specific inhibitor of AAA+ ATPase motor cytoplasmic dynein. Ciliobrevin D inhibits Hedgehog (Hh) signaling and primary cilia formation. Ciliobrevin D inhibits dynein-dependent microtubule gliding and ATPase activity in vitro .

HY-12788A

(S)-PF-04449613	Phosphodiesterase (PDE)	Neurological Disease
(S)-PF-04449613 is the left-handed isomer of PF-04449613 (HY-12788). PF-04449613 is a selective PDE9A inhibitor with an IC₅₀ of 22 nM. PF-04449613 improves motor learning ability in a mouse model .

Cat. No.	Product Name

HY-L085

Anti-Parkinson's Disease Compound Library

1354 compounds

Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.

MCE offers a unique collection of 1354 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

HY-L086

Neurodegenerative Disease-related Compound Library

2255 compounds

Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.

MCE offers a unique collection of 2255 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

HY-L165

Dopamine Receptor Compound Library

199 compounds

Dopamine receptor (DAR), widely distributed in the brain, plays a key role in regulating motor function, motivation, driving force and cognition. The role of DA is mediated by D1-type (D1, D5) and D2-type receptors (D2S, D2L, D3, D4), which are distributed in presynaptic, postsynaptic and extrasynaptic, projection neurons and interneurons. Each receptor has a different function. D1 and D5 receptors couple with G stimulation sites and activate Adenylyl cyclase. The activation of Adenylyl cyclase leads to the production of the second messenger cAMP, which leads to the production of protein kinase A (PKA), which leads to further transcription in the nucleus. D2 to D4 receptors are coupled to G inhibitory sites to inhibit adenylyl cyclase and activate potassium Ion channel. These receptors utilize phosphorylation cascades or direct membrane interactions to affect the functions of voltage-gated and neurotransmitter-gated channels, cytoplasmic enzymes, and transcription factors. Dopamine receptor plays an important role in daily life.

MCE designs a unique collection of 199 small molecules related to dopamine receptor. It is a good tool for screening drugs from nervous system disease.

Cat. No.	Product Name	Target	Research Area

HY-P1297

CRF(6-33)(human)	CRFR	Neurological Disease
CRF(6-33)(human) is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) has anti-obesity effect .

HY-149941

hNTS1R agonist-1	Neurotensin Receptor	Neurological Disease
hNTS1R agonist-1 (Compound 10) is a BBB permeable hNTS1R full agonist (K_i: 6.9 nM) . hNTS1R agonist-1 increases motor function and memory in a mouse model of Parkinson's disease (PD). hNTS1R agonist-1 is a Neurotensin(8-13) analog and is a neuroprotective agent .

HY-P1297A

CRF(6-33)(human) TFA	CRFR	Neurological Disease
CRF(6-33)(human) TFA is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) TFA competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) TFA has anti-obesity effect .

HY-P5808

Iota-conotoxin RXIA	Peptides	Neurological Disease
lota-conotoxin RXIA is an agonist of voltage-gated sodium channels (Na_v1.2, 1.6, 1.7). Iota-conotoxin RXIA can induce repetitive action potential and seizure in motor axons of frogs after intracranial injection in mice .

HY-P10019

Pegsebrenatide NLY01	GCGR	Neurological Disease
Pegsebrenatide (NLY01) is a long-acting GLP-1R agonist. Pegsebrenatide has an extended half-life and favorable blood-brain barrier penetration. Pegsebrenatide can block A1 astrocyte transformation, reducing dopaminergic cell death, and improving motor symptoms in mouse models of PD .

HY-148195

NNZ 2591	Peptides	Neurological Disease
NNZ 2591 is a synthetic analogue of a small peptide of cyclic glycine proline (cGP). NNZ 2591 shows orally active and cross the blood-brain barrier. NNZ 2591 shows neuroprotective after ischemic brain injury. NNZ 2591 improves motor function in a rat model of Parkinson's disease. NNZ 2591 has the potential for the research of ischemic brain injury and angelman syndrome .

HY-P3801

[Glp5,(Me)Phe8,Sar9] Substance P (5-11) DiMe-C7	Neurokinin Receptor	Others Neurological Disease Metabolic Disease
[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is a Substance P (HY-P0201) analogue that has approximately the same effects as Substance P (HY-P0201) on neurokinin 1 receptor (NK1R) in rat brain, but with a much longer duration of action. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) selectively activates dopamine metabolism in the mesencephalon and midbrain cortex of the rat brain. [Glp5,(Me)Phe8,Sar9] Substance P (5-11) also increases motor activity and induces recovery of addictive agent-seeking behavior in rats .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N11128

Solidagonic acid	Structural Classification Terpenoids Source classification Diterpenoids Solidago altissima Linnaeus Plants Compositae	Kinesin
Solidagonic acid inhibits HSET motor activity by promoting the conversion from abnormal monopolar to bipolar spindles. Solidagonic acid suppresses fission yeast cell death and enables reversion of the mitotic spindles from a monopolar to bipolar morphology. Solidagonic acid showed the growth inhibitory activity on the seedlings of Lactuca sativa L. and Lolium multiflorum Lam .

Species:	Human (3)
Tag:	His (2) Tag Free (3)
Source:	E. coli (5)

Cat. No.	Compare	Product Name	Species	Source

HY-P73635

	SMNDC1/SPF30 Protein, Human (His) Survival of motor neuron-related-splicing factor 30; SMNDC1; SMNR; SPF30	Human	E. coli
	SMNDC1/SPF30 Protein is pivotal in spliceosome assembly, forming associations with spliceosomes, U4/U5/U6 tri-snRNP, and U2 snRNP. Its Tudor domain directly interacts with SNRPD3, emphasizing its crucial role in essential interactions within the splicing machinery and contributing to the intricate process of pre-mRNA splicing. SMNDC1/SPF30 Protein, Human (His) is the recombinant human-derived SMNDC1/SPF30 protein, expressed by E. coli , with N-6*His labeled tag. The total length of SMNDC1/SPF30 Protein, Human (His) is 238 a.a., with molecular weight of ~29 kDa.

HY-P71366

	TIM-14 Protein, S.cerevisiae Mitochondrial import inner membrane translocase subunit TIM14; Presequencetranslocated associated motor subunit PAM18; PAM18; TIM14	Others	E. coli
	The TIM-14 protein is an important component of the PAM complex and is required for the transport of transit peptide-containing proteins from the inner membrane to the mitochondrial matrix using ATP. TIM-14 Protein, S.cerevisiae is the recombinant TIM-14 protein, expressed by E. coli , with tag free. The total length of TIM-14 Protein, S.cerevisiae is 70 a.a., with molecular weight of ~9.0 kDa.

HY-P71367

	TIM-16 Protein, S. cerevisiae Mitochondrial import inner membrane translocase subunit TIM16; Presequence translocated-associated motor subunit PAM16; PAM16; TIM16	Others	E. coli
	TIM-16 protein is an important component of the PAM complex, which uses ATP to promote the transfer of transit peptide-containing proteins from the inner membrane to the mitochondrial matrix. TIM-16 Protein, S. cerevisiae is the recombinant TIM-16 protein, expressed by E. coli , with tag free. The total length of TIM-16 Protein, S. cerevisiae is 66 a.a., with molecular weight of ~11.0 kDa.

HY-P701378

	KIF11 Protein, Human KIF11; Kinesin-like protein KIF11; Kinesin-like protein 1; Kinesin-like spindle protein HKSP; Kinesin-related motor protein Eg5; Thyroid receptor-interacting protein 5; TR-interacting protein 5; TRIP-5	Human	E. coli
	KIF11 Protein, a pivotal motor protein, orchestrates mitotic spindle formation and aids in Golgi-to-surface protein transport. Beyond mitosis, it engages in complex interactions, binding to thyroid hormone receptor, participating in chromatin remodeling, and interacting with NEK6, RARRES1, and AGBL2. This multifaceted role highlights KIF11's diverse contributions to cellular processes. KIF11 Protein, Human is the recombinant human-derived KIF11 protein, expressed by E. coli , with tag free. The total length of KIF11 Protein, Human is 368 a.a., .

HY-P701379

	KIF11 Protein, Human (His) KIF11; Kinesin-like protein KIF11; Kinesin-like protein 1; Kinesin-like spindle protein HKSP; Kinesin-related motor protein Eg5; Thyroid receptor-interacting protein 5; TR-interacting protein 5; TRIP-5	Human	E. coli
	KIF11 Protein, a pivotal motor protein, orchestrates mitotic spindle formation and aids in Golgi-to-surface protein transport. Beyond mitosis, it engages in complex interactions, binding to thyroid hormone receptor, participating in chromatin remodeling, and interacting with NEK6, RARRES1, and AGBL2. This multifaceted role highlights KIF11's diverse contributions to cellular processes. KIF11 Protein, Human (His) is the recombinant human-derived KIF11 protein, expressed by E. coli , with N-6*His labeled tag. The total length of KIF11 Protein, Human (His) is 368 a.a., .

Cat. No.	Product Name	Chemical Structure